Binimetinib
Brand names: Mektovi · Active ingredient: Binimetinib
In short: MEKTOVI is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test . MEKTOVI is indicated, in combination with encorafenib, for the treatment of adult patients with met
What is Binimetinib used for?
MEKTOVI is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test .
MEKTOVI is indicated, in combination with encorafenib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. .
Binimetinib dosage
BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma
Confirm the presence of a BRAF V600E or V600K mutation in tumor specimens prior to initiating MEKTOVI . Information on FDA-approved tests for the detection of BRAF V600E and V600K mutations in melanoma is available at: http://www.fda.gov/CompanionDiagnostics.
BRAF V600E Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)
Confirm the presence of a BRAF V600E mutation in tumor or plasma specimens prior to initiating MEKTOVI . If no mutation is detected in a plasma specimen, test tumor tissue. Information on FDA-approved tests for the detection of BRAF V600E mutations in NSCLC is available at: http://www.fda.gov/CompanionDiagnostics.
The recommended dosage of MEKTOVI is 45 mg orally taken twice daily, approximately 12 hours apart, in combination with encorafenib until disease progression or unacceptable toxicity. Refer to the encorafenib prescribing information for recommended encorafenib dosing information.
MEKTOVI may be taken with or without food . Do not take a missed dose of MEKTOVI within 6 hours of the next dose of MEKTOVI.
Do not take an additional dose if vomiting occurs after MEKTOVI administration but continue with the next scheduled dose.
If encorafenib is permanently discontinued, discontinue MEKTOVI.
Dose reductions for adverse reactions associated with MEKTOVI are presented in Table 1.
Action | Recommended Dose
First Dose Reduction | 30 mg orally twice daily
Subsequent Modification | Permanently discontinue if unable to tolerate MEKTOVI 30 mg orally twice daily
Dosage modifications for adverse reactions associated with MEKTOVI are presented in Table 2.
Severity of Adverse Reaction
National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. | Dose Modification for MEKTOVI
Cardiomyopathy
•Asymptomatic, absolute decrease in LVEF of greater than 10% from baseline that is also below lower limit of normal (LLN) | Withhold MEKTOVI for up to 4 weeks, evaluate LVEF every 2 weeks.Resume MEKTOVI at a reduced dose if the following are present:
•LVEF is at or above the lower limit of normal and
•Absolute decrease from baseline is 10% or less and
•Patient is asymptomatic.
If the LVEF does not recover within 4 weeks permanently discontinue MEKTOVI.
•Symptomatic congestive heart failure or absolute decrease in LVEF of greater than 20% from baseline that is also below LLN | Permanently discontinue MEKTOVI.
Venous Thromboembolism
•Uncomplicated deep venous thrombosis (DVT) or pulmonary embolism (PE) | Withhold MEKTOVI.
•If improves to Grade 0-1, resume at a reduced dose.
•If no improvement, permanently discontinue MEKTOVI.
•Life threatening PE | Permanently discontinue MEKTOVI. …
How to take Binimetinib — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Inform patients of the following:
New Primary Malignancies
Advise patients that MEKTOVI administered with encorafenib can result in the development of new primary cutaneous and non-cutaneous malignancies. Advise patients to contact their healthcare provider immediately for any new lesions, changes to existing lesions on their skin, or other signs and symptoms of malignancies .
Cardiomyopathy
Advise patients to report any symptoms of heart failure to their healthcare provider .
Venous Thromboembolism
Advise patients to contact their healthcare provider if they experience symptoms of venous thrombosis or pulmonary embolism. Advise patients to seek medical attention for sudden onset of difficulty breathing, leg pain, or swelling .
Ocular Toxicities
Advise patients to contact their healthcare provider as soon as possible if they experience any changes in their vision .
Interstitial Lung Disease
Advise patients to contact their healthcare provider if they experience any new or worsening respiratory symptoms including cough or dyspnea . …
Warnings & precautions
Do not take this medicine if: None.
New primary malignancies, cutaneous and non-cutaneous, can occur when MEKTOVI is used in combination with encorafenib.
In PHAROS, cutaneous squamous cell carcinoma and skin papilloma each occurred in 2% of patients who received MEKTOVI in combination with encorafenib.
Monitor patients for new malignancies prior to initiation of treatment, while on treatment, and after discontinuation of treatment .
Cardiomyopathy, manifesting as left ventricular dysfunction associated with symptomatic or asymptomatic decreases in ejection fraction, has been reported in patients treated with MEKTOVI in combination with encorafenib. In COLUMBUS, evidence of cardiomyopathy (decrease in LVEF below the institutional LLN with an absolute decrease in LVEF ≥10% below baseline as detected by echocardiography or MUGA) occurred in 7% of patients receiving MEKTOVI plus encorafenib. Grade 3 left ventricular dysfunction occurred in 1.6% of patients. The median time to first occurrence of left ventricular dysfunction (any grade) in patients receiving MEKTOVI in combination with encorafenib was 3.6 months (range 0 to 21 months). Cardiomyopathy resolved in 87% of patients receiving MEKTOVI plus encorafenib.
In PHAROS, evidence of cardiomyopathy (decrease in LVEF below the institutional LLN with an absolute decrease in LVEF ≥10% below baseline as detected by echocardiography or MUGA) occurred in 11% of patients receiving MEKTOVI in combination with encorafenib. Grade 3 left ventricular dysfunction occurred in 1% of patients. Cardiomyopathy resolved in 82% of patients receiving MEKTOVI plus encorafenib.
Assess ejection fraction by echocardiogram or MUGA scan prior to initiating treatment, one month after initiating treatment, and then every 2 to 3 months during treatment. …
Binimetinib side effects
The following adverse reactions are described elsewhere in the labeling:
•New Primary Malignancies
•Cardiomyopathy
•Venous Thromboembolism
•Ocular Toxicities
•Interstitial Lung Disease
•Hepatotoxicity
•Rhabdomyolysis
•Hemorrhage
•Embryo-Fetal Toxicity
•Risks Associated with Combination Treatment
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data described in WARNINGS AND PRECAUTIONS reflect exposure of 192 patients with BRAF V600 mutation-positive unresectable or metastatic melanoma to MEKTOVI 45 mg twice daily in combination with encorafenib 450 mg once daily in a randomized open-label, active-controlled trial (COLUMBUS) or, for rare events, exposure of 690 patients with BRAF V600 mutation-positive melanoma to MEKTOVI 45 mg twice daily in combination with encorafenib once daily across multiple clinical trials (NCT03915951, NCT01909453).
The pooled safety population described in the WARNINGS AND PRECAUTIONS also reflect exposure of 98 patients with BRAF V600E mutation-positive metastatic non-small cell lung cancer to MEKTOVI 45 mg twice daily and encorafenib 450 mg once daily until disease progression or unacceptable toxicity in PHAROS . …
Drug interactions
No clinically important drug interactions have been observed with MEKTOVI.
About this medicine
Binimetinib is a kinase inhibitor. The chemical name is 5-[(4-bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide. The molecular formula is C17H15BrF2N4O3 and the molecular weight is 441.2 daltons. The chemical structure of binimetinib is shown below:
Binimetinib is a white to slightly yellow powder. In aqueous media, binimetinib is slightly soluble at pH 1, very slightly soluble at pH 2, and practically insoluble at pH 4.5 and higher.
MEKTOVI (binimetinib) tablets for oral use contain 15 mg of binimetinib with the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate (vegetable source), and colloidal silicon dioxide. The coating contains polyvinyl alcohol, polyethylene glycol, titanium dioxide, talc, ferric oxide yellow, and ferrosoferric oxide.
How it works: Binimetinib is a reversible inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activity. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 6c3408ac-d401-4925-8a03-26591afbc240. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate